Skip to Main Content
Skip Nav Destination






(vi NOR el been)

Brand Names: US

  • Navelbine [DSC]

Therapeutic Category

  • Antineoplastic Agent, Antimicrotubular
  • Antineoplastic Agent, Vinca Alkaloid

Medication Safety Issues

Sound-alike/look-alike issues:

Vinorelbine may be confused with vinBLAStine, vinCRIStine

Vinorelbine (50 mg/5 mL; Hospira manufacturer) may be confused with conventional cytarabine (100 mg/5 mL; Hospira manufacturer) due to similar packaging; potential for inadvertent intrathecal administration of vinorelbine may occur (ISMP [Smetzer 2015]).

High alert medication:

This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.

Administration issues:

Vinorelbine is for IV administration only: Inadvertent intrathecal administration of other vinca alkaloids has resulted in death. The ISMP strongly recommends dispensing vinca alkaloids in a minibag, and NOT a syringe (ISMP 2020). Vinorelbine should NOT be prepared during the preparation of any intrathecal medications. After preparation, keep vinorelbine in a location away from the separate storage location recommended for intrathecal medications

This item requires a subscription. For full access to this content, please log in to an existing user account or purchase an individual subscription. If you have an active subscription and appear logged in (your name appears in the upper right corner), but you cannot access content, please click the “Log Out” option under your name and log back in.
Close Modal

or Create an Account

Close Modal
Close Modal